TY  - JOUR
AU  - Spigel, D R
AU  - Vicente, D
AU  - Ciuleanu, T E
AU  - Gettinger, S
AU  - Peters, S
AU  - Horn, L
AU  - Audigier-Valette, C
AU  - Pardo Aranda, N
AU  - Juan-Vidal, O
AU  - Cheng, Y
AU  - Zhang, H
AU  - Shi, M
AU  - Luft, A
AU  - Wolf, J
AU  - Antonia, S
AU  - Nakagawa, K
AU  - Fairchild, J
AU  - Baudelet, C
AU  - Pandya, D
AU  - Doshi, P
AU  - Chang, H
AU  - Reck, M
PY  - 2021
DO  - 10.1016/j.annonc.2021.01.071
UR  - http://hdl.handle.net/10668/17105
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus...
LA  - en
KW  - PD-1
KW  - biomarkers
KW  - immunotherapy
KW  - small-cell lung cancer
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Humans
KW  - Lung Neoplasms
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
KW  - Progression-Free Survival
KW  - Small Cell Lung Carcinoma
TI  - Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆.
TY  - research article
VL  - 32
ER  -